Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 6/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.59 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.44 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7547844 | 0.90 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25324799 | 0.87 | FFAR1 (0.51) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7428096 | 0.83 | MEN1 (0.55) | — | |
| SCHEMBL16321856 | 0.83 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL93039 | 0.82 | OPRD1 (0.48) | SLC6A2SLC6A4SLC6A3SOS1OPRD1 | |
| SCHEMBL9381630 | 0.82 | SOS1 (0.45) | SLC6A2SLC6A4SLC6A3SOS1OPRD1 | |
| SCHEMBL966816 | 0.81 | MEN1 (0.58) | — | |
| Hydrochloric Acid SCHEMBL15535996 | 0.81 | SLC6A2 (0.71) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13476484 | 0.81 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14095780 | 0.81 | SLC6A4 (0.52) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131079-A1 | FLUFENOXINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF AMYLOID PATHOLOGIES | FAES FARMA, S.A. (ES) | 2013-05-23 | — | — | US | disclosed |
| EP-2576509-A1 | FLUFENOXINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF AMILOYD PATHOLOGIES | Faes Farma, S.A. (ES) | 2013-04-10 | — | — | EP | disclosed |
| CN-103025714-A | Flufenoxine derivatives for the treatment and prevention of amiloyd pathologies | FAES FARMA SA | 2013-04-03 | — | — | CN | disclosed |
| WO-2011147780-A1 | FLUFENOXINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF AMILOYD PATHOLOGIES | FAES FARMA, S.A. (ES) | 2011-12-01 | — | — | WO | disclosed |
| EP-2390248-A1 | Flufenoxine derivatives for the treatment and prevention of amiloyd pathologies | FAES FARMA, S.A. (ES) | 2011-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131079-A1 | FLUFENOXINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF AMYLOID PATHOLOGIES | APP, MAPT, PSEN1 | SLC6A2 173/4885SLC6A4 325/4885SLC6A3 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.